Oncology Biomarkers Market Outlook Signals Expansion To $33.63 Billion Through 2030

The oncology biomarkers market is positioned for significant expansion as personalized medicine and advanced diagnostic technologies continue to evolve. With cancer diagnostics becoming more precise and tailored, the demand for effective biomarker solutions is rapidly increasing. Let's delve into the market's projected growth, leading players, emerging trends, and segmentation to understand the dynamics shaping this critical healthcare sector.

Projected Market Growth and Size of the Oncology Biomarkers Market
The oncology biomarkers market is anticipated to grow swiftly in the upcoming years, reaching a valuation of $33.63 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 14.3%. Several factors are driving this expansion, including the rising demand for personalized oncology therapies, advancements in AI-powered biomarker discovery, increased funding in cancer genomics, wider adoption of liquid biopsy techniques, and a stronger emphasis on early cancer detection and continuous monitoring. Key trends influencing market development during this period involve greater use of precision oncology diagnostics, enhanced focus on genetic and protein biomarkers, deeper integration of bioinformatics in biomarker analysis, expansion in companion diagnostics, and a growing commitment to personalized cancer treatment approaches.

Download a free sample of the Oncology Biomarkers market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Top Companies Leading the Oncology Biomarkers Market
The oncology biomarkers market is currently dominated by a number of influential companies, including F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton dic*kinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, and OncoDNA SA.

In May 2023, Freenome, a private biotech firm based in the United States, acquired UK-based Oncimmune Ltd. for an undisclosed price. This strategic acquisition aims to strengthen Freenome's clinical and commercial capabilities to support its forefront cancer screening initiatives. Additionally, the deal will enhance Freenome's multi-omics platform to provide a more comprehensive understanding of the tumor microenvironment. Oncimmune Ltd. specializes in immunodiagnostics, focusing on immune-oncology, autoimmune diseases, and infectious conditions.

View the full Oncology Biomarkers market report:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Current Trends Shaping the Oncology Biomarkers Sector
Leading players in oncology diagnostics are concentrating on developing innovative biomarker assays that enhance early cancer detection, track minimal residual disease (MRD), and assess therapeutic responses. MRD represents the small population of cancer cells that may persist after treatment and could cause relapse if not identified early. For example, in May 2024, Tempus, a US company specializing in AI and precision medicine, launched its MRD test portfolio, which includes the xM test and the xM (NeXT Personal Dx) test created by Personalis. These tests offer both tumor-naïve and tumor-informed assays engineered to detect early cancer recurrence, monitor residual disease, and evaluate patient reactions to immunotherapy. By utilizing circulating tumor biomarkers, these advanced tests equip clinicians with sensitive and actionable data critical for patient care decisions.

Further Trends Driving Innovation in Oncology Biomarkers
The industry is also witnessing growing integration of artificial intelligence and bioinformatics to improve biomarker identification and clinical utility. These technologies facilitate faster and more accurate analysis of complex biological data, enabling personalized treatment regimens and better patient outcomes. Moreover, the development of companion diagnostics is gaining momentum, supporting targeted therapies by linking biomarker status directly with therapeutic decision-making. This focus on precise diagnostics fuels ongoing advancements and investment within the oncology biomarkers market.

Detailed Segmentation of the Oncology Biomarkers Market
This report segments the oncology biomarkers market into several categories for a clearer understanding of its structure:

1) By Biomarker Type: including Protein Biomarkers, Genetic Biomarkers, and Other Biomarker Types.
2) By Cancer Type: encompassing Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, and other types of cancer.
3) By Application: covering Diagnostics, Research and Development, Prognostics, Risk Assessment, and other uses.
4) By End-User: consisting of Hospitals, Academic and Cancer Research Institutes, and Diagnostic Laboratories.

Further subsegments are defined as follows:
- Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), and Enzymatic Biomarkers.
- Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, and Single Nucleotide Polymorphisms (SNPs).
- Other Biomarker Types: Metabolomic Biomarkers, Epigenetic Biomarkers, and MicroRNA Biomarkers.

This comprehensive segmentation highlights the diverse range of biomarker categories and cancer types targeted by diagnostic and research efforts, reflecting the complex landscape of oncology biomarker applications.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.